DCPH stock forecast
Our latest prediction for Deciphera Pharmaceuticals, Inc.'s stock price was made on the Aug. 16, 2019 when the stock price was at 37.00$.
In the short term (2weeks), DCPH's stock price should underperform the market by -0.77%. During that period the price should oscillate between -12.12% and +14.26%.
In the medium term (3months), DCPH's stock price should outperform the market by 1.37%. During that period the price should oscillate between -22.06% and +32.07%.Get email alerts
About Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
At the moment the company generates 25M USD in revenues.
On its last earning announcement, the company reported a loss of -3.99$ per share.
The book value per share is 8.78$
Three months stock forecastAug. 16, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|